PET/CT in the Evaluation of Inflammatory Bowel Disease: Studies in Patients Before and After Treatment
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The purpose of this study was to evaluate the appropriate 2-deoxy-2-[18F]fluoro-d-glucose–positron emission tomography (FDG-PET) determination in patients with inflammatory bowel disease (IBD) before and after clinical improvement to see if this determination correlates with clinical activity.
We performed PET–computed tomography (PET/CT) on five patients before and after successful medical therapy in patients with moderately active IBD. Each patient had five bowel segments scored (0–3) for the appropriate FDG-PET determination.
There were five patients [Crohn’s disease (CD) = 3, ulcerative colitis = 2] who were studied an average of 437 days (range, 77–807) after initial PET/CT scan. All patients showed significant improvement in physician global assessment scores (p = 0.004) and underwent repeat PET/CT. The total score of all segments was 32 pretreatment and 14 posttreatment (p < 0.01). Of 11 pretreatment active segments, nine (82%) segments either became inactive or displayed decreased activity, while two showed no change (p < 0.001).
Appropriate FDG-PET determination decreases with successful treatment of inflammation in active IBD and correlates with symptom improvement.
Manuscript Category and Significance
- Skehan SJ, Issenman R, Mernagh J, Nahmias C, Jacobson K (1999) 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 354:836–837 (PMID: 10485733)
- Lemberg DA, Issenman RM, Cawdron R et al (2005) Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 11:733–738 (PMID 16043988) CrossRef
- Neurath MF, Vehling D, Schunk K et al (2002) Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97:1978–1985 (PMID: 12190164) CrossRef
- Pio BS, Byrne FR, Aranda R et al (2003) Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-d-glucose-labeled white blood cells. Mol Imaging Biol 5:271–277 (PMID: 14499142) CrossRef
- Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP (2006) High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072:379–385 (PMID: 17057218) CrossRef
- Meisner RS, Spier BJ, Einarsson S et al (2007) Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13:993–1000 (PMID: 17394243) CrossRef
- Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R (2007) Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 48:1053–1059 (PMID: 17574978) CrossRef
- Best WR, Becktel JM, Singleton JW, Kern F Jr (1976) Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology 70:439–444
- Sutherland L, Singleton J, Sessions J et al (1991) Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 32:1071–1075 CrossRef
- Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s-disease activity. Lancet 1:514 CrossRef
- PET/CT in the Evaluation of Inflammatory Bowel Disease: Studies in Patients Before and After Treatment
Molecular Imaging and Biology
Volume 12, Issue 1 , pp 85-88
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Inflammatory bowel disease
- Crohn’s colitis
- Ulcerative colitis
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology and Hepatology, University of Wisconsin Hospital and Clinics in Madison, Madison, WI, USA
- 2. Department of Radiology, University of Wisconsin Hospital and Clinics in Madison, Madison, WI, USA